- Exchange: SIX Swiss Ex
- Sector: Consumer, Non-cyclical
- Industry: Pharmaceuticals
- Sub-Industry: Medical-Drugs
Roche Holding AG
+ Add to WatchlistROG:VX
258.500 CHF 7.500 2.99%
Share
As of 11:43:58 ET on 05/22/2013.
More on ROG
News for Roche Holding AG (ROG)
-
COMPANY NEWS
-
PRESS RELEASES
-
INDUSTRY NEWS
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campus
- Glaxo Sees Emerging Market Price Cuts Driving Drug Volume Growth
- Bristol-Myers Drug Cocktail Stymies Melanoma Tumors
- Swiss Stocks Drop as Zurich Insurance Retreats on Profit
- Roche Experimental Leukemia Drug Helps Shrink Tumors
- Nintendo, Apple, Samsung, Metso: Intellectual Property
- Roche Wins FDA Approval for Test to Target Lung Cancer
- Swiss Stocks Rise, Extending Five-Year High; Adecco Gains
- Human Immune-Boosting Cancer Drugs Seen Extending Lives
- Bristol-Myers, Disney, Google: Intellectual Property
- Bristol-Myers Sues Genentech Over ‘Cabilly’ Patents
- Novartis Boost Seen in Fast Approvals as Protection Ends
- Roche’s Skin-Cancer Drug Erivedge Wins EU Agency Backing
- Swiss Stocks Advance as U.K. Economy Grows, Nobel Gains
- Genentech and Biogen Idec Have Filed for a Re-hearing of U.S. Court of Appeals Decision in the Arzerra Patent Infringement Case Published May 17, 2013
- Diabetes Care Club Acquires Priority Diabetes Supply, Obtains CMS Contract to Distribute Diabetic Supplies Published May 16, 2013
- Genentech’s Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Published May 15, 2013
- New Roche Award for Antibody-based Cancer Therapy Research Published May 15, 2013
- Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO Published May 15, 2013
- FDA Approves Tarceva (Erlotinib) Tablets and Cobas EGFR Mutation Test for Specific Type of Lung Cancer Published May 14, 2013
- Nuvilex Inc. Reminiscent of Major Biotech Success Stories Published May 14, 2013
- Phillip Malone to Direct New Juelsgaard Intellectual Property and Innovation Clinic at Stanford Law School Published May 13, 2013
- Curis Announces Approval of Erivedge(R) in Australia Published May 10, 2013
- Drugs.com Releases Q1 Sales for Top 100 U.S. Drugs: Rough U.S Flu Season Boosts Numbers for Tamiflu Published May 06, 2013
- FDA Approves ACTEMRA® for Children Living with a Rare Form of Arthritis Published Apr 30, 2013
- Curis Reports First Quarter 2013 Financial Results Published Apr 30, 2013
- Afraxis Appoints Carmine Stengone President and Chief Executive Officer, and Christopher Rex, Ph.D., Chief Scientific Officer Published Apr 29, 2013
- Curis Announces Erivedge(R) Receives Positive CHMP Opinion for Conditional Approval in European Union Published Apr 26, 2013
- ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2013 Financial Results and Provides Quarterly Update Published Apr 26, 2013
- Emerging-Market ETF Drops Most in 1 Month as Mexico Sinks Updated 3 hours ago
- U.S. Stocks Fall on Concern Fed Will Scale Back Stimulus Updated 3 hours ago
- Merck Insomnia Drug Is Safe Only in Lower Doses, Panel Says Updated 3 hours ago
- Pfizer to Split Off Rest of Zoetis Animal Health Business
- BioMarin Gains on Prospects for Experimental Cancer Drug
- New Flu Vaccine Beats Current Products in Animal Testing
- Europe Stocks Little Changed as Bernanke Backs Bond Plan
- Novartis Ramps Up Alzheimer’s Drug Pursuit as Rivals Fail
- Hedge Funds Trail S&P 500 by 10 Percentage Points, Goldman Says
- India Said to Seek Review of U.S. Court Ruling Papers on Ranbaxy
- Swiss Billionaires Buy Merck Geneva Building for Biotech Campus
- The Top Ten Stocks for Wednesday, May 22
- Apple Got No Sweetheart Accord on Corporate Tax Bill, Irish Say
- Glaxo to Get Up to $200 Million for U.S. Research
- Kasowitz Benson, Eversheds, Latham: Business of Law
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Advertisements
Advertisement
Rate this Page